The Effects of Acute and Chronic Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
NCT05876923
Recruiting
This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients with indolent non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +1 locations
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent Non-hodgkin Lymphoma
Register for Updates
Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD
NCT05929911
Recruiting
People living with HIV (PLWH) have a higher rate of post-traumatic stress disorder (PTSD) diagnosis than the general population. Comorbid PTSD is also associated with negative HIV-related health outcomes. Unfortunately, little outcome research has examined the usefulness of PTSD treatments for PTSD. This pilot study adapts for PLWH a non-exposure based psychotherapy for PTSD focused on reflecting on one's emotions and relationships and understanding and working through how trauma may have disrup... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/04/2025
Locations: Albert Einstein College of Medicine, Bronx, New York
Conditions: Post Traumatic Stress Disorder, HIV
Register for Updates
Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES
NCT05968898
Recruiting
This is a pragmatic clinical trial that will study the effect of a radiomics-based computer-aided diagnosis (CAD) tool on clinicians' management of pulmonary nodules (PNs) compared to usual care. Adults aged 35-89 years with 8-30mm PNs evaluated at Penn Medicine PN clinics will undergo 1:1 randomization to one of two groups, defined by the PN malignancy risk stratification strategy used by evaluating clinicians: 1) usual care or 2) usual care + use of a radiomics-based CAD tool.
Gender:
ALL
Ages:
Between 35 years and 89 years
Trial Updated:
06/04/2025
Locations: Penn Medicine University City, Philadelphia, Pennsylvania +2 locations
Conditions: Lung Cancer, Pulmonary Nodule, Solitary
Register for Updates
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT05996003
Recruiting
This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered once weekly. The study consists of 2 parts: Part 1 and Part 2. Six participants (Cohort 1) will participate in both Part 1 and Part 2, and 14 participants (Cohort 2) will be added for Part 2.
Gender:
MALE
Ages:
Between 4 years and 14 years
Trial Updated:
06/04/2025
Locations: Children's Hospital Colorado, Aurora, Colorado +7 locations
Conditions: Duchenne Muscular Dystrophy
Register for Updates
An Exercise Intervention to Improve Overall Brain Health
NCT06035094
Recruiting
The goal of this clinical trial is to test the effects of 10 weeks of exercise on overall brain health, reduction in blood pressure, and the number of blood vessels in the back of the eyes in patients with hypertension and have a body mass index ≥ 25 kg/m2. The main question\[s\] it aims to answer are: * To test the effect of moderate vs intensive exercise on Brain Care Score outcomes. * To ascertain the differential impact of moderate vs high intensity exercise in reducing hypertension and its... Read More
Gender:
ALL
Ages:
Between 35 years and 65 years
Trial Updated:
06/04/2025
Locations: UAB, Birmingham, Alabama
Conditions: Brain Care Score, Exercise, Hypertension, BMI
Register for Updates
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
NCT06113302
Recruiting
To learn if luspatercept is more effective in helping to reduce the number of blood transfusions needed by patients with LR-MDS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Myelodysplastic Syndromes
Register for Updates
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
NCT06116890
Recruiting
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/04/2025
Locations: Barnet Dulaney Perkins Eye Center - Phoenix, Mesa, Arizona +83 locations
Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Register for Updates
Investigation of Inflammation in Alzheimer's Disease and Related Dementias (ADRD) Using [11C]-CS1P1
NCT06129838
Recruiting
This study involves a brain positron emission tomography (PET) scan with a new, investigational radioactive tracer called \[11C\]-CS1P1 to identify inflammation in the brain by testing with healthy older adults and with cognitively impaired older adults.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/04/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Alzheimer Disease
Register for Updates
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT06131398
Recruiting
The primary objectives of this study are to: * Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors * Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/04/2025
Locations: City of Hope National Medical Center, Duarte, California +24 locations
Conditions: Advanced Solid Tumors
Register for Updates
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
NCT06137807
Recruiting
The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcatheter Bicaval Valves are pre-mounted into the TricValve® Delivery System which is used for percutaneous access and delivery of the TricValve® Transcatheter Bicaval Valve in the vena cava. The system i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona +35 locations
Conditions: Tricuspid Regurgitation, Tricuspid Valve Disease
Register for Updates
Identifying Networks Underlying Compulsivity in Anorexia Nervosa for Targeting With Neuromodulation
NCT06138782
Recruiting
Transcranial Magnetic Stimulation (TMS) is approved by the Food and Drug Administration (FDA) for the treatment of refractory Major Depressive Disorder (MDD) and obsessive-compulsive disorder (OCD). Anorexia nervosa (AN) is characterized by restrictive eating leading to low weight and associated complications. There is an emerging understanding that the symptoms of OCD and AN overlap as AN can be characterized by obsessive thought patterns around food and compulsive restricting and weight loss b... Read More
Gender:
ALL
Ages:
Between 16 years and 75 years
Trial Updated:
06/04/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Anorexia Nervosa
Register for Updates
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
NCT06140524
Recruiting
The primary purpose of the study is to understand how well the study drug can eliminate abnormal plasma cells and laboratory signs of high-risk monoclonal gammopathy of undetermined significance (HR-MGUS) and non high-risk smoldering multiple myeloma (NHR-SMM). This requires understanding the safety and tolerability of the study drug (how the body reacts to linvoseltamab) as well as the effectiveness of the study drug (how well linvoseltamab eliminates plasma cells). All participants will start... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland +11 locations
Conditions: Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
Register for Updates